Herzliya, Israel and Calgary, Alberta–(Newsfile Corp. – September 15, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce today, that it has completed a cosmetic clinical study examining the impact of its SHIR ™ Premium CBD Facial Serum containing 300 mg of cannabidiol (“CBD“) (the “Serum”) on skin hydration.
To view an enhanced version of Table 2, please visit:
The study was conducted by an independent research laboratory: INOVAPOTEK, Pharmaceutical Research and Development in Portugal”. The study aimed to assess the hydrating efficacy of the Serum in vivo, by measuring the skin capacitance for a period of 2, 4, 8 and 24 hours after the CBD Serum application on the skin. The results demonstrated that there were significant hydration increases for each period. The Serum was well tolerated with no uncomfortable symptoms or